Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study

Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Chen Saijuan, Zhu Chen, Xinxin Zhang, Xiaoming Yang
doi: https://doi.org/10.1101/2020.03.16.20036145
Kai Duan
1China National Biotec Group Company Limited, 15F, Block 2, Fortune Tower, No.4 HuiXin East Street, Chaoyang District, Beijing 100029, China
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bende Liu
3First People’s Hospital of Jiangxia District, No.1 Wenhua Road, Jiangxia District, Wuhan 430200, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cesheng Li
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huajun Zhang
5CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega- Science, Chinese Academy of Sciences, 44 Xiao Hong Shan, Wuhan 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting Yu
6WuHanJinyintan Hospital, No.1 Jin Yin Tan Road, Dongxihu District, Wuhan 430023, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jieming Qu
7Department of Respiratory and Critical Care Medicine, National Research Center for Translational Medicine (Shanghai,NRCTMS), Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Zhou
7Department of Respiratory and Critical Care Medicine, National Research Center for Translational Medicine (Shanghai,NRCTMS), Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Chen
8Clinical Research Center, Department of Gastroenterology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Xiwang Road 999, Jiading District, Shanghai 200018, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shengli Meng
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Hu
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Peng
5CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega- Science, Chinese Academy of Sciences, 44 Xiao Hong Shan, Wuhan 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingchao Yuan
9Wuhan Blood Center, No.8 BaoFeng First Road, Qiaokou District, Wuhan 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinyan Huang
10State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, NRCTMS, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zejun Wang
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhong Yu
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoxiao Gao
5CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega- Science, Chinese Academy of Sciences, 44 Xiao Hong Shan, Wuhan 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Wang
9Wuhan Blood Center, No.8 BaoFeng First Road, Qiaokou District, Wuhan 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoqi Yu
11Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, NRCTMS, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Li
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiayou Zhang
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao Wu
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bei Li
5CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega- Science, Chinese Academy of Sciences, 44 Xiao Hong Shan, Wuhan 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanping Xu
7Department of Respiratory and Critical Care Medicine, National Research Center for Translational Medicine (Shanghai,NRCTMS), Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Chen
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Peng
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yeqin Hu
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianzhen Lin
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuefei Liu
7Department of Respiratory and Critical Care Medicine, National Research Center for Translational Medicine (Shanghai,NRCTMS), Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shihe Huang
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhijun Zhou
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianghao Zhang
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yue Wang
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi Zhang
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kun Deng
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiwu Xia
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qin Gong
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Zhang
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaobei Zheng
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Liu
4Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd, No.1A Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huichuan Yang
1China National Biotec Group Company Limited, 15F, Block 2, Fortune Tower, No.4 HuiXin East Street, Chaoyang District, Beijing 100029, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dongbo Zhou
1China National Biotec Group Company Limited, 15F, Block 2, Fortune Tower, No.4 HuiXin East Street, Chaoyang District, Beijing 100029, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ding Yu
1China National Biotec Group Company Limited, 15F, Block 2, Fortune Tower, No.4 HuiXin East Street, Chaoyang District, Beijing 100029, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jifeng Hou
12National Institute for Food and Drug Control of China, No.29 HuaTuo Road, Daxing District, Beijing 102629, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengli Shi
5CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega- Science, Chinese Academy of Sciences, 44 Xiao Hong Shan, Wuhan 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen Saijuan
10State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, NRCTMS, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhu Chen
10State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, NRCTMS, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yangxiaoming@sinopharm.com zhangx@shsmu.edu.cn zchen@stn.sh.cn
Xinxin Zhang
11Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, NRCTMS, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yangxiaoming@sinopharm.com zhangx@shsmu.edu.cn zchen@stn.sh.cn
Xiaoming Yang
1China National Biotec Group Company Limited, 15F, Block 2, Fortune Tower, No.4 HuiXin East Street, Chaoyang District, Beijing 100029, China
2National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co.Ltd., No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan 430207, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yangxiaoming@sinopharm.com zhangx@shsmu.edu.cn zchen@stn.sh.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65×109/L vs. 0.76×109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

Significance Statement COVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explored the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was welltolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 days. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 days. Radiological examination showed varying degrees of absorption of lung lesions within 7 days. These results indicate that CP can serve as a promising rescue option for severe COVID-19 while the randomized trial is warranted.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000030048

Funding Statement

This study was funded by Key projects of the Ministry of Science and Technology China “Preparation of specific plasma and specific globulin from patients with a recovery period of COVID-19 infection” (project number: 2020YFC0841800).This work was also supported by Shanghai Guangci Translational Medicine Development Foundation.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data associated with the manuscript were available on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Chen Saijuan, Zhu Chen, Xinxin Zhang, Xiaoming Yang
medRxiv 2020.03.16.20036145; doi: https://doi.org/10.1101/2020.03.16.20036145
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Chen Saijuan, Zhu Chen, Xinxin Zhang, Xiaoming Yang
medRxiv 2020.03.16.20036145; doi: https://doi.org/10.1101/2020.03.16.20036145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (198)
  • Anesthesia (54)
  • Cardiovascular Medicine (492)
  • Dentistry and Oral Medicine (90)
  • Dermatology (56)
  • Emergency Medicine (169)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (212)
  • Epidemiology (5706)
  • Forensic Medicine (3)
  • Gastroenterology (217)
  • Genetic and Genomic Medicine (870)
  • Geriatric Medicine (88)
  • Health Economics (232)
  • Health Informatics (763)
  • Health Policy (394)
  • Health Systems and Quality Improvement (254)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6497)
  • Intensive Care and Critical Care Medicine (391)
  • Medical Education (118)
  • Medical Ethics (28)
  • Nephrology (93)
  • Neurology (850)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (263)
  • Oncology (515)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (251)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (972)
  • Public and Global Health (2237)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (313)
  • Rheumatology (109)
  • Sexual and Reproductive Health (81)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)